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A B S T R A C T
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of
countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically
related to the SARS coronavirus and has also been associated with severe respiratory illness as well as
nosocomial transmission in healthcare settings. Current international recommendations do not support
any specific therapies; however, there are a number of agents, which were used during the SARS
epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have
reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to
their potential use in patients with MERS-CoV infections.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Coronaviruses are RNA viruses which usually cause mild upper
respiratory illnesses. The emergence of SARS (severe acute
respiratory Syndrome) MERS (Middle east respiratory syndrome)
has focussed global attention on the clinical significance of
cornaviruses.
The current Middle East Respiratory Syndrome Novel corona-
virus (MERS-CoV) was first isolated in June 2012 from the
respiratory tract of a businessman in the Bisha area of Saudi
Arabia, who subsequently died of pneumonia and renal failure.1 As
of 28 July 2013 MERS-CoV has caused 91 laboratory confirmed
cases and 46 deaths, representing a high case fatality rate of 50%.2
The high case fatality rate is likely related to the pattern of the
disease as we probably are seeing only the tip of the iceberg of
critically ill and admitted patients. The high fatality rate is likely to
decline as milder clinical cases emerge. Similar to SARS, common* Corresponding author. P.O. Box 76, Room A-428-2, Building 61, Dhahran Health
Center, Saudi Aramco, Dhahran 31311, Saudi Arabia. Tel.: +966 3 877 3524;
fax: +966 3 877 3790.
E-mail addresses: jaffar.tawfiq@aramco.com, jaltawfi@yahoo.com
(J.A. Al-Tawfiq).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.07.002symptoms in patients with MERS-CoV include fever, cough,
shortness of breath, and gastrointestinal symptoms. Most patients
have had pneumonia and the majority was reported to have
multiple co-morbid conditions.3,4
The rapid deployment of effective therapeutics is a high priority
as there is currently no specific therapy or vaccine for MERS-CoV.
The clinical experience from SARS suggests that a number of
interventions including ribavirin with and without corticosteroids,
interferon alfa with corticosteroids, ribavirin with lopinavir and
ritonavir, and convalescent plasma may improve the outcome in
patients but the data are not conclusive.5
The purpose of this review is first to summarize the
effectiveness of these treatments, in an attempt to identify a
therapeutic approach that could help select the most appropriate
therapeutic options for patients with MERS-CoV infections.
2. Methods
We systematically searched the literature databases (PubMed,
Science Direct and the Cochrane database) for published studies.
We used the key words ‘‘SARS’’, ‘‘coronavirus’’, in combination with
‘‘treatment’’, human studies, randomized controlled trials (RCT),
prospective or retrospective cohort designs, case-control designs,ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Summary of Ribavarin Therapy in the treatment of SARS patients
Reference 
#
Type of 
study
Dose # patient s Time of 
administration
Outcome
8 IV loading dose 2g 
then 1 g IV q6h x 4 
days then 500 mg IV  
Q8h x 4-6 days
7 Upon admission to a 
medical ward 
Outcome N= 7
Died  2
Improved within 5 days 5
- Recovered completely 3
- mild dyspnea with 3 weeks 
follow-up
2
9 9 patients on 8mg/kg 
IV q8H
1 patient on 1.2 g po 
Q8h
(Duration of therapy 
not mentioned)
10 Upon admission Inconclusive  
Outcome N=10
Died with respiratory failure 2
Resolution of fever and improvement 
in heart rate within 2 days
8
Recovered completely 1
Able to walk on the level without 
apparent restriction
4
Able to walk 3-5 steps on the level 3
Mild dry cough 4
10 Loading dose of 2 g 
40% received steroids; 
Most patients received 
approximately 20 to 50 
IV, then 1 g IV q6h for
4d, then 500 mg q8h for
3d The median treatme nt
was 6d.
mg/d of hydrocortisone
for 10 days. One patient
received pulse steroid.
111 91% started on ribavirin 
within the first 48hr 
of hospitalization. 
<20% received steroid 
in the first 48 hours. 
Ribavirin was associated with significant toxicity
Ribavirin toxicity N= 111
Hemolysis (%) 76
Decrease in hemoglobin of 2 g/dL 
(%)
49
Admitted to the ICU (%) 20
21-day mortality 6.5%
Possible harm
11 Retrospective 
cohort study
(LOE,II)
PO 20 mg/kg TID
versus
Oseltamivir, 75 mg 
BID
Ribavirin (n= 14)
Oseltamivir (n=6)  
Most of patients at day 
10-14 of symptoms. Outcome Oseltamivir
N=6
Ribavirin
N=14
improved sufficiently
to be extubated
2 0
required mechanical 
ventilation
0 6
died of progressive 
respiratory failure
 0 3
Inconclusive
There is no obvious response to ribavirin, and several 
patients deteriorated in spite of its use. In contrast, a 
number of patients recovered without use of ribavirin.
12 Prospective 
observational 
study
(LOE, II)
IV 8mg/kg Q8h for 
14days + 
hydrocortisone 200 mg 
IV Q8 h over 10 days, 
then PO prednisolone 
1mg/kg for 5 days, 0 5 
mg/kg for
3 days, and 0 25 
mg/kg for 3 days.
pulses of 
methylprednisolone 
500 mg IV OD  for
2-3 doses
75 After diagnosis 
of SARS 
Worsening in week 2 is unrelated to uncontrolled viral 
replication but may be related to immunopathological  
damage.
Outcome
Death* 5 (7%)
Convalescence at home or at 
rehabilitation facility
27  
(36%)
Hospital admission
In general ward
29  
(39%)
In intensive-care unit for ARDS 13 
(17%)
*Two patients died of acute myocardial infarction, one
of clinical sepsis, and two of clinical sepsis and ARDS
Inconclusive
Observational
(LOE, III) 
Observational
(LOE, III) 
Retrospective
case series
(LOE, II)   
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13 Randomized
control trial
(LOE,II2)
190 patients
A
(40)
B
(30)
C (60) D (60)
ribavirin IV
interf
eron-
alpha
 IM
No Yes Some 45 patient
Antibi
otics
C-S AZ,
FQ
 AZ,
FQ
 AZ, LF
AZ  =azithromycin, FQ  =quinolone; LF =  
levofloxacin
Steroids were added (methyl prednisolone
80–160 mg OD for
2–3 days) when symptoms worsened.
In group D few patients  received high dos e
methylprednisolone up to 1000 mg/daily
At the time
of admission Factor A B C D
Resolution
of pyrexia
(days)
9.4 ±
3.6
6.7  ±
1.9
7.2
±
2.8
3 ± 1.4
Respiratory
improvemen
t (days)
10.9
± 7.3
9.8  ±
5.1
7.8
±
3.9
5.9 ± 2.6
require
mechanical
ventilation
 3 2 8 0
Deaths 2 2 7 0
Resolution of pyrexia and respiratory improvement
was significantly better in group D (p> 0.05)
14 Prospective
cohort study
(LOE, II)
156 patients
cefotaxime +  PO levofloxaci n
or clarithromycin + Oseltamivir
or
PO ribavirin loading dose 2.4 g then 1.2 g
TID + prednisolone 0.5–1 mg/kg/day),
patient  with dyspnea were treated with
IV ribavirin 400 mg Q8h + hydrocortisone
100 mg Q8h).
or
Pulses of methylprednisolone 0.5 g IV
infusion for 3 days.
After 48h of persistent
fever Broad
spectrum
antimicrobial
(n = 138)
Ribavirin
+ steroid
(n =
138)
methylprednisolone`
IV (n = 107)
Sustained
response
0 (0) 16
(11.6%)
50 (46.7%)
Partial
response
0 (0) 9
(6.5%)
45 (42.1%)
No
response
138
(100%)
113
(81.9% )
12 (11.2%)
Possible harm
15 Retrospective
(LOE II)
40 patients
 Treatment consisted of Ribavarin with either
intravenous or oral
hydrocortisone with or without one
pulsed steroid regime (intravenous
methylprednisolone 500 mg per day for
3–5 days)
mean time of 3.4 days  ±
3.6 (median, 2 days;
range, 1–19 days) after
admission
Inconclusive.  There was no mention of the total
number of respondents. It is rather surprising that
patients with long treatment delay had a good response.
This is partly related to that the allocation to different
regimens was not randomized and the criteria not
described in the paper.  Parameters that influenced
treatment response were time from symptom onset to
treatment day (P=0.003), time from admission to
treatment day (P=0.001), time to maximal
radiographic score from treatment day (P=0 .001),
maximal radiographic score (P=0.009), SaO2 at
maximal radiographic score (P= 0.13).
16 retrospective
cohort study
(LOE, II)
229patients
(97 ribavirin)
PO1.2 g TID or IV 400 mg Q8h
Versus
 no treatment
at a mean of 6.4 days of
illness
Use of ribavirin did not confer any benefit for patients
 with SARS.
Outcome Non -
ribavirin
(%, n =
132)
Ribavi
rin (%,
n = 97)
P-value
Number
of death
(%)
17 (12.9) 10
(10.3)
0.679
Number
of ever
admitted
to ICU
(%)
27 (20.5) 19
(19.6)
>0.999
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and ritonavir (LPV/r), and convalescent plasma. We exclude
corticosteroid studies as this was beyond the scope of this review
and the management of severe pneumonia has been well covered
in the WHO guideline.6
Data extracted from these publications include: authors name,
publication year, type of study, level of evidence, sample size,
interventions dose, duration, indication, route, and time of
administration, number of patients, and efficacy and safety
outcome of these interventions. The outcomes of interest included
mortality rate, measures of morbidity and adverse effects. The
outcomes reported in the selected studies included death,
mechanical ventilation, improvement of symptoms, admission
to the intensive care unit, infectious complications, successful
discharge and adverse effects.
3. Assessment of study quality
The clinical studies were all critically appraised. Aspects that
were assessed included study design, the possibility of bias in the
selection of the control group and treatment allocation, and
whether the treatment regimen and reporting of outcomes were
consistent. The studies were tabulated and summarized in a
narrative way, and were grouped by the treatment strategy. We
categorized each article depending on which drug was used. We
tabulated results as type of study, dose, duration, time of
administration, and indication of medication, number of patients
included in that study, plus the final outcomes.Table 2
Lopinavir/Ritonavir studies
Reference
# 
Type of 
study 
Regimen # patients  Indication   Time of
administration 
17 Cohort 
study 
(LOE, II) 
Ribavirin for 10-14days
(2.4 g PO loading dose, 
followed by 1.2 g PO Q8h, 
or 
8 mg/kg IV Q8h, if the 
patient could 
not  tolerate oral treatment), 
+ corticosteroid therapy for 
21 days
(hydrocortisone 100-200 mg 
Q 6-8 hours, or 
methylprednisolone 
3 mg/kg/day, depending on 
severity) 
If no response pulses 
of methylprednisolone 500-
1000 mg IV OD  were used  
as rescue therapy, 
then + lopinavir 400 
mg/ritonavir 100 mg PO 
Q12h for 10 to 14 days 
1052 
patients  
SARS In newly 
diagnosed patient
rescue 
therapy  later in 
course of the 
when patients had
worsening sympto
18 
Cohort 
(LOE, II) 
Historical group: 
Ribavirin for 
14 days (4 g PO loading 
dose followed by 1.2 g Q8h, 
or 8 mg/kg IV Q8h  
+  
corticosteroid for 21 days 
(starting dose: 
hydrocortisone 
100–200 mg Q 6–8 hours or  
methylprednisolone 
3 mg/kg/day). Pulses of IV 
methylprednisolone 
(0.5–1 g/day up to 4 g) if 
needed 
Treatment group: 
+
lopinavir 
(400 mg)/ritonavir (100 mg) 
PO Q12h for 
14 days 
41 patients 
treated, 111 
Historical 
(152) 
SARS 
Newly diag 
SARS patients w
ARDS The studies were scored using the US Preventive Services Task
Force scoring system7, where Level of Evidence.
LOE, I: Evidence obtained from at least one properly designed
randomized controlled trial.
Level II-1: Evidence obtained from well-designed controlled
trials without randomization.
Level II-2: Evidence obtained from well-designed cohort or
case-control analytic studies, preferably from more than one
center or research group.
Level II-3: Evidence obtained from multiple time series with or
without the intervention. Dramatic results in uncontrolled
trials might also be regarded as this type of evidence.
Level III: Opinions of respected authorities, based on clinical
experience, descriptive studies, or reports of expert commit-
tees.
4. Results
We identified 54 studies about SARS or coronavirus and we
included 19 studies only. We excluded 35 studies since 14 of them
were in vitro studies, 15 corticosteroid studies, and 6 were non-
therapeutic studies. Overall, we analyzed 19 studies, nine used
ribavirin alone or with interferon (Table 1)8–16, two used lopinavir
and ritonavir (Table 2)17,18, six used convalescent plasma
(Table 3)19–22, there was one study of Interferon alpha (Table 4)23
and one study comparing Interferon alpha versus ribavirin13.
Summaries of the different studies are presented in Tables 1–4.Outcome 
; or as
 th e
illness
 
ms 
The addition of lopinavir/ritonavir to a standard treatment protocol 
as an initial treatment appeared to be 
associated with improved clinical outcome and reduce death rate 
The addition of lopinavir/ritonavir to a standard treatment protocol 
As a rescue for SARS no clinical improvement. The authors report a significant effect  
(p<0.05) on  death rate,ventilater rater rates and proportion requiring 
methylprednisolone pulse 
LPV/r
, n=44 
cohort, 
 n=634 
Death rate (%) 2.3 15.6 
Intubation rate (%) 0 11 
Desaturation rate (%) 68.2  84.5  
Proportion requiring 
pulse 
methylprdnisone (%) 
27.3 55.4  
Mean pulse 
methylprednisolone 
dose  (G) 
1.6 3.0 
nosed
ith no
Patients treated with lopinavir/ritonavir appea red to run a milder disease course in terms 
of diarrhea, recurrence of fever, and worsening of chest radiographs. A reduction in the 
viral load, reduction in steroid usage and nosocomial infections was seen in 
patients initially treated with lopinavir/ritonavir 
Historical 
controls 
(n = 111) 
Treatment 
group 
(n = 41) 
p value 
Development 32 (28.8%)   1 (2.4%) <0.001 
Death/ARDS 
at day 21 
7 (6.3%)/25 
(22.5 
%) 0 (0%)/1 
(2.4%) 
- 
of ARDS or
death within
21 days 
Table 3
Convalescent Plasma studies
Reference 
# 
Type of study Regimen # patients Indication  Time of  
administration 
Outcome 
19 
Cohort study 
(LOE,II)  
Convalescent plasma (500 
mL) was obtained from 
each of three SARS 
patients and transfusedinto  
the 3 infected HCW. 
3 patients SARS 
No date was given All three patients survived. One healthcare worker became pregnant subsequently,  
delivering 13 months after 
discharge. 
20 
Case report 
(LOE, III) 
infusion of plasma 
collected (200ml) from  a 
convalescent patient with  
SARS to treat, in  
combination with 
ribavirin and 
corticosteroids 
One patient SARS 
On day 14 of  
hospitalization 
The clinical outcome  was successful, despite  the relatively low volume of plasma  
infused; furthermore, no side-effects were observed 
21 
Cohort 
(LOE, II) 
200-400ml (4-5ml/kg) of 
|ABO compatible 
convalescent plasma 
80 patients   
On day 14 of starting 
symptoms 
Mortality rate 12.5% compared to 17% of SARS patient 
22 
Retrospective 
cohort study 
(LOE, II) 
ribavirin + 
methylprednisolone 3 
doses (500 mg each) of 
pulsed 
methylprednisolone 
200-400 ml of  
convalescent plasma 
(plasma group) or further 
pulses of 
methylprednisolone 
(steroid group) 
200–400 mL of   
30 SARS  
At the discretion of  
theattending 
clinicians and  
according to the 
availability of  
convalescent plasma.
 
 Plasma  
group 
(n= 19) 
Steroid group  
(n= 21) 
P valu e
Discharge rate by day 22 
Following onset of    illness 
73.4% N= 14 19% N= 4 0.001 
Discharge rate by day 22 after  
adjustment for co-morbidities 
77.8% 
(14/18) 
23% 
(3/13)  
0.004 
Death rate 0% 23.8% 
(n=5) 
0.049 
Inconclusive  
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Table 4
Interferon alpha studies
Reference
# 
Type of 
study 
Regimen  # patients  Indication  Time of administration  Outcome  
23 
Retrospect i
ve cohort 
study 
(LOE,II) 
Prednisone PO 50mg 
BID or IV 
methylprednisolone  
40mg Q12h if not 
control IV 
methylprednisolone  
500mg OD for 3 days 
then taper and step 
down to PO 
prednisone to 
complete 20days 
SQ interferon 
alfacone-1 for 10 
days starting with 
9mcg/d for at least 2 
days then 15 mcg/d if 
no response for 8-13 
days 
28 SARS 
When health Canada 
approval for interferon 
alfacone-1 use in SARS 
treatment (may 29, 2003) 
Resolution of fever and lymphopenia were similar 
between groups 
corticosteroid
s alone 
(n= 13) 
interferon 
alfacon-1 
(9) 
transferred to 
the intensive 
care unit 
5 (38.5%) 3 (33.3%) 
required 
intubation 
3 (23.1%) 1 (11.1%) 
died 1 (7.7%) 0 (0%) 
The interferon alfacon-1 treatment group had a shorter 
time to 50% resolution of lung radiographic 
abnormalities (P =.001), had better oxygen saturation (P 
=.02), resolved their need for supplemental oxygen more 
rapidly ( P =.02), had less of an increase in creatine 
kinase levels (P =.03), and showed a trend toward more 
rapid resolution of lactate dehydrogenase levels 
compared with the group receiving corticosteroids 
alone. 
Inconclusive  
and mechanical  
ventilation 
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There has been a lot of concern worldwide about the emergence
of the MERS-CoV. Although infection control, molecular diagnos-
tics and international public health have improved considerably
since the 2003 SARS epidemic, there are still no proven or licensed
therapies for any coronavirus infection. The high mortality
associated with MERS-CoV led us to conduct this systematic
review to summarize the available options for treatment for novel
coronavirus infection based on previous reports of therapy of SARS,
a related coronavirus.
The most commonly used agent was the broad spectrum
antiviral ribavirin. There were seven reports of the use of ribavirin
in SARS patients although only four reported control groups. The
mortality benefit was inconsistent with mortality rates of between
5% and 42.8%,8–14 two studies showed improvements of symptoms
in 71.4%-80% of patients, and ICU admission rates of 13%-20%.8,9
The major problem with ribavirin was the significant incidence of
adverse events especially hemolysis which was reported in
68.5%.10Table 5
Possible dosages and schedule of therapeutic agents for MERS-CoV Infection
Medication Normal dose
Crc l> 50ml/min
Impaired renal function
Crcl (20-50 ml/min)
ES
C
Ribavirin oral  2000 mg loading dose then   
1200mg q8h for 4 days, 
then 600mg po q8h for 4-6 
days 
2000 mg loading dose 
then  600 mg po q8h for 
4 days,  200 mg po q6h 
for 4-6 days 
200
then  
day
Peg 
interferon alfa 
2b 
1.5mcg/kg once per week x 
2 
Same dose 
Lopinavir 400 mg/ 
ritonavir 100 mg 
oral
Lopinavir 400 mg/ ritonavir 
100 mg twice daily for 10 
days. May be given in 
combination with Ribavirin
Same dose 
convalescent 
plasma
300- 500 ml of full plasma  
(3 – 5 ml/kg) With a rate of 
2ml/min for one time in day 
2 of ICU admission.
Same dose The timing of the start of antiviral agents is important in most
virus infections. One study compared oseltamivir versus ribavirin
and showed no obvious response to ribavirin, however, the
treatment were started after 10-14 days of symptoms which might
have led to the poorer outcomes.11
There was only one randomized controlled trial: this compared
ribavirin versus interferon-1a and showed no advantage of
ribavirin over interferon in patients with SARS.13 In addition,
there were observational studies comparing Interferon-1a with
untreated controls.23 Interferon led to improvements in clinical
and laboratory parameters compared with control patients.23
However, there was no standard regime used and adverse events
were not well documented.
The addition of lopinavir/ritonavir to ribavirin regimen was
associated with improved clinical outcome and reduces the death
rate comparing to ribavirin regimen alone in observational
studies.17,18 These studies are detailed in Table 2.
Few studies addressed the effect of convalescent plasma.19–22
These studies were mainly case reports which limit the generaliz-
ability of their findings. In three studies of SARS patients, patientsRD (Hemodialysis)
rCl< 20ml/min
0 mg loading dose 
200mg po q6h for 4 
s, then 200mg po 
q12h 
Same dose
Same dose
Same dose 
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versus 15.6%- 19%; P < 0.001)21,22 and lower mortality than the
comparator group (0%- 12.5% versus 17% 23.8%).19,21,22
Intriguingly, an in vitro study showed that convalescent plasma
from SARS patients might contain cross-reactive antibodies against
other beta-coronavirus including MERS-CoV.24 Of 28 sera, 7 (25%)
had antibodies anti-MERS-CoV neutralizing antibodies at low
titers.24 Convalescent sera was recommended in a recent study by
the International Severe Acute Respiratory and Emerging Infection
Consortium (ISARIC).25 Cross- reactive antibodies may be present
in convalescent plasma from SARS patients against other beta-
coronavirus and may be associated with a better outcome, reduced
mortality, and shorter hospital stay.19–22 There are considerable
technical hurdles to overcome before convalescent sera can be
widely recommended as a therapeutic agent in the modern era.
Currently, there is a need to establish a serology test to diagnose
patients with mild disease and thus identify those patients as
possible donors of convalescent sera.
We conclude that the use of ribavirin may improve the outcome
and reduce mortality as shown in a number of studies. One of the
reasons for the failure of ribavirin in some reports may have been the
timing for the use of ribavirin, after 6-14 days of symptom,11,14,16
compared to studies which showed benefits when ribavirin was
started within 48 hours of hospitalization or after diagnosis of SARS
was established.8,9,12,13The major limitation of Ribavarin is its
significant toxicity at the doses used to treat patients with SARS.
Although the addition of lopinavir/ritonavir to ribavirin appeared to
have a better outcome in patients with SARS.17,18 There are reports
that lopinavir/ritonavir is not active in vitro against the MERS-CoV.25
Other in vitro studies have failed to yield potent therapeutic agents
despite a search including DPP4 inhibitors.26
Among the limitations of this review are the heterogeneity of the
reviewed studies in terms of the wide range of treatment dosages,
frequency, and route of administration, duration, and timing of
administration. The reported treatment effects should be inter-
preted with caution due to the lack of randomized, controlled trials.
Also, while we have drawn on the SARS literature, and SARS is a
closely related virus, there are clearly differences between SARS and
the MERS-CoV and the data might not be able to be directly
extrapolated to MERS-CoV infected patients. The use of the discussed
agents would require monitoring hematological and biochemical
parameters during treatment to detect and prevent adverse effects
associated with therapy. Possible dosages of discussed agents
especially with unavailability of intravenous ribavarin are listed in
Table 5. The table also includes the possible dosage of pegelated
interferon-a (PegIFN—a) that is commonly used in the treatment of
hepatitis C virus infection. PegIFN-a was 50-100 times more effective
in vitro for MERS-CoV than SARS-CoV.25The long half-life of PegIFN-a
and the associated adverse effects calls for extra attention for the use
of shorter-acting interferon.25 The use of interferon therapy with
ribavirin is not recommended in patients with hepatitis C virus
infection and renal dysfunction (Clcr <50 mL/minute).
With the emergence of MERS-CoV and the lack of high quality
clinical evidence to support recommendations for the use of available
therapeutic options, there is a clear need for developing protocols
to be used in randomized-controlled trials in order to determine
the most effective therapies for this novel emerging pathogen.
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